Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
GILEAD SCIENCES, INC. (CIK 882095) reported $2.12B across 6 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: ACLX ($771.7M, 36.44%), RCUS ($678.8M, 32.05%), GLPG ($501.2M, 23.67%), ASMB ($125.0M, 5.90%), KYTX ($35.6M, 1.68%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ACLX | Arcellx Inc | $771.7M | 36.44% | 6.7M | Hold |
| 2 | RCUS | Arcus Biosciences Inc | $678.8M | 32.05% | 31.4M | Hold |
| 3 | GLPG | Galapagos NV | $501.2M | 23.67% | 16.7M | Hold |
| 4 | ASMB | Assembly Biosciences Inc | $125.0M | 5.90% | 4.5M | Hold |
| 5 | KYTX | Kyverna Therapeutics Inc | $35.6M | 1.68% | 4.1M | Hold |
| 6 | XLO | Xilio Therapeutics Inc | $5.5M | 0.26% | 650,389 | Trimmed |
Source: SEC Form 13F filings · as of 2026-03-31